kw2871
mAbexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2004 (NCT00199342)
Timeline
Indications
Studied for
Mechanism of action
- Ganglioside GD3OTHER
Ganglioside GD3 other
Immunostimulant. Binds to GD3-positive cells, thereby initiating antibody-dependent cytotoxicity against GD3-positive cells and complement-mediated cytotoxicity.
- Ganglioside GD3ADCC
ganglioside GD3
- Ganglioside GD3Immunity, passive
Ganglioside GD3 immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109057 ↗
Also known as
- ecromeximab
- ecromeximab
- km-871
- kw-281
- kw2871
- kw2871
- kw-2871
- kw-2871
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00679289 | Phase 2 | Mar 1, 2008 | Life Sciences Pharmaceuticals, Ludwig Institute for Cancer Research, University of Pittsburgh |
| NCT00199342 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2004 | Kyowa Hakko Kirin, University of Alabama |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kyowa Hakko Kirin | For profit | 1 | 1 | 1 | 2004 |
| Life Sciences Pharmaceuticals | For profit | 1 | 0 | 1 | 2008 |
| Ludwig Institute for Cancer Research | Academic/Hospital | 1 | 1 | 1 | 2008 |
| University of Alabama | Academic/Hospital | 1 | 0 | 1 | 2004 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2008 |
5 organizations
Page 1 / 1